Better Context → Better Decisions
Context counts in life sciences. The FENIX analyst team is tirelessly using its experience to put you in a position to succeed. Below, our readers with corporate access will find a wealth of contextualized life science insight ready to be viewed in the FENIX Marketplace.
Welcome to FENIX Syndicated Services. If you already have an account, please log in. If you have any questions or would like to subscribe to our services, please contact us.
$599
Posted in: GLP-1RA Apr 11 | 2023FENIX Analysis: Lilly Oral GLP-1RA Pivotal ProgramPurchase Blast
$599
Posted in: Basal Insulin, Other, SGLT2i Apr 04 | 2023Lannett Announces Positive Pivotal Bs-Glargine Results; Mark Cuban’s Pharmacy Offers Janssen’s Invokana; Diamyd Partners with JDRF for Ph3 Diamyd T1DM DevelopmentPurchase Blast
$599
Posted in: Other Apr 03 | 2023NeuroBo Submits NASH IND; New Akebia Vadadustat Data; Arrowhead Earns $30M Milestone Payment from GSKPurchase Blast
$599
Posted in: GLP-1RA, Other Mar 31 | 2023Wegovy and Entresto Receive Positive CHMP Opinions for Pediatric Indication ExtensionsPurchase Blast
$599
Posted in: Other Mar 30 | 2023Akero to Initiate Ph3 NASH Program; Bigfoot Acquires Insulin Titration Algorithm; GSK Collaborates with PathAI in NASHPurchase Blast
$599
Posted in: GLP-1RA, Other Mar 29 | 2023FDA Releases Framework for Use of Digital Health Technology in Clinical Trials; New Ph2 Dapiglutide Obesity TrialPurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Other Mar 28 | 2023Viking Announces Positive Ph1 GLP-1/GIP Dual Agonist Topline Results and Initiates Oral Formulation Development; Zealand Ph1a Amylin Analog Results; Biomea Ph2 Menin Inhibitor ResultsPurchase Blast
$599
Posted in: Dual/triple agonist, Other Mar 27 | 2023Mounjaro Obesity Indication Filed in EU; March CHMP Agenda; Vertex Announces T1DM Licensing Agreement with CRISPR; Sanofi Helps Dario Secure Top-Ten PBM ContractPurchase Blast
$599
Posted in: GLP-1RA Mar 24 | 2023Positive High-Dose Oral Semaglutide Topline ResultsPurchase Blast
$599
Posted in: Other Mar 22 | 202389bio Positive Ph2b Pegozafermin NASH Data; Novartis Discontinues Inclisiran UK Primary Prevention Trial; Novo Nordisk Partners with Dewpoint Therapeutics; Evkeeza Receives Pediatric ApprovalPurchase Blast
$599
Posted in: GLP-1RA Mar 21 | 2023Altimmune Ph2 Obesity and Ph1b T2DM Pemvidutide DataPurchase Blast
$599
Posted in: Glucose Monitoring, Other Mar 21 | 2023Senseonics Q4 ’22 Earnings and CGM Investor Event; OrsoBio Doses First Patient in Ph2 TLC-3595 Trial for Insulin ResistancePurchase Blast
$599
Posted in: Basal Insulin, Bolus Insulin Mar 17 | 2023Sanofi Follows Lilly and Novo's Insulin Price CutsPurchase Blast
$599
Posted in: Glucose Monitoring, Other Mar 15 | 2023Nemaura Includes Insulin in EU DuoPack License Agreement; Sigilon Q4 ‘22 EarningsPurchase Blast
$599
Posted in: Basal Insulin, Bolus Insulin Mar 14 | 2023Novo Nordisk to Lower US Insulin PricesPurchase Blast$599
Posted in: Other Mar 13 | 2023Sanofi Acquires Provention Bio; Ozempic Takes Stage at OscarsPurchase Blast
$599
Posted in: Dual/triple agonist, Other Mar 10 | 2023Mounjaro TV DTC Analysis; Intercept OCA Adcom SetPurchase Blast
$599
Posted in: Other Mar 09 | 2023Vertex Announces FDA Clearance of IND for VX-264 in T1DM; Akebia and Dario Q4 ’22 EarningsPurchase Blast